Loading Events

Webinar #19 – Correcting Premature Stop Codon Mutations using Anticodon Edited Transfer RNA

  • This event has passed.

December 4, 2020 @ 6:30 pm – 7:00 pm

Here are our introductory comments:

‍Drs. George and Ahern have teamed up to create a treatment that will be useful for many different diseases.  They leverage basic biology to create a tool that will “read through” a premature stop within a protein.  Who does this help?  In fact, many of the Syngap1 pathogenic variants (and pathogenic variants for many diseases) are caused by single-base changes in the DNA that result in premature termination of the protein.  The changes that will be targeted by their treatment are called nonsense variants because they do not code for an amino acid at that point, but encode a “stop”  instead so that the protein-making machinery stops before synthesizing the complete protein.

Dr. George gives a great overview of the basic biology behind the tRNA read-through concept.  Dr. Ahern discusses how a treatment might get delivered with an Adeno-Associated Virus (AAV), and importantly shows that the treatment does not have off-target effects.  Dr. Ahern describes the next steps in developing a clinical treatment, including making mouse models with protein-truncating variants to test.

The initial results showing no off-target effects are stunning, are applicable to many genes and many patients.

THIS IS FOR TRANSCRIPT ONLY:

0:02move on to our next

0:04um speakers i think we’re going to have

0:05a tag team of speakers here

0:08um with dr al george and dr

0:11um christopher ahern and so i’ll

0:13introduce them both

0:16and then let them take uh take you can

0:18go ahead and get your slides ready if

0:19you’d like

0:20um so um dr george is the professor andSynGap Research Foundation 2nd Annual SynGAP Roundtable

0:23chair of the department of pharmacology

0:25and director of the center for

0:26pharmacogenomics at northwestern

0:28university school of medicine he

0:30also directs the ninds-funded

0:33channelophasy-associated epilepsy

0:35research

0:36center without walls which was recently

0:39funded and is a large collaborative

0:41effort to

0:43uh catalog mutations and effects of

0:45those mutations in uh

0:46ion channels christopher ahern is a

0:49professor in the department of molecular

0:50physiology and biophysics and a member

0:52of the iowa neuroscience institute

0:54at university of iowa um near and dear

0:57to my heart

0:58i grew up near there um and he has

1:00developed a platform of gene therapy

1:02technology

1:03uh engineering transfer rnas used to

1:05correct premature termination

1:07uh determination codons i think we’re

1:08going to hear a little from both of them

1:10in the next half hour

1:11thank you all right thank you very much

1:13heather and

1:14i want to thank the organizers

1:18particularly mike and hans for inviting

1:21me and allowing me to tag team today

1:24with my friend and colleague chris ahern

1:26from the university of iowa to tell you

1:28a little bit about a conceptual

1:31approach to correcting

1:34a certain class of mutations in syngap1

1:38and these are premature stop codon

1:40mutations and i’ll

1:41give a little bit of an introduction

1:43with some background especially for

1:45members of the audience

1:46who aren’t familiar with the nuances of

1:48molecular biology

1:50and then i’ll turn it over to chris for

1:52him to share with you

1:53his uh brilliant and and elegant

1:56technology for

1:57rescuing stop codons uh premature stop

2:00codons and then i’ll take it back

2:01for just uh some final words about what

2:04we’re cooking up

2:05that could be applied to syngap1

2:08so let me start by just sharing with youGenes to Proteins: Molecular Biology

2:11sort of the big picture

2:12this is what is often referred to as the

2:14central dogma

2:15of molecular biology it’s what we’ve

2:18come to understand

2:19is the flow of genetic information from

2:22the cell which contains

2:24the dna that is transcribed into rna

2:28and then the rna is translated into

2:30protein and certainly anywhere along

2:32this

2:33pathway one can have a genetic mutation

2:35that disrupts the process

2:37and thwarts the effort to make an

2:40important biologically active protein

2:42but today we’re going to focus a lot on

2:44things that disrupt the translation step

2:47and results in incompetent proteins

2:50being made so translation involves

2:54the reading of messenger rna

2:58by an organelle called the ribosome

3:01and ribosomes scan messenger rna

3:05almost like a barcode reader would read

3:07a a

3:08series of barcoded instructions in the

3:11case of the ribosome

3:13the barcode is actually clusters or

3:16groupings

3:17of three nucleotides present in the rna

3:20sequence

3:21and each of these three clusters of

3:23three nucleotides

3:24if read properly in the right sequence

3:27will

3:28code for a specific sequence of

3:31amino acids in a protein and so theTranslation of mRNA Requires Transfer RNAs

3:34process of reading the rna

3:35involves a specialized type of rna

3:38called

3:39transfer rnas that are depicted here

3:41schematically

3:42and these are small very small rna

3:45molecules

3:46that are built to recognize

3:49the bar codes in messenger rna and

3:53couple that recognition with the

3:56coupling

3:56with a coupling of the molecule to an

3:59amino acid

4:01and then the process is directed by the

4:03genetic code

4:04each triplet codon in the mrna sequence

4:07or the barcode

4:09is defines a specific amino acid

4:13so the process of translating mrnaMessenger RNA Directs Protein Synthesis

4:16sequence

4:16into a protein is graphically

4:18illustrated here where

4:20the ribosome docks to messenger rna it

4:23recognizes

4:24a first codon known as the start codon

4:27which codes for methionine residues in a

4:29protein

4:31that allows the cognate transfer rna

4:34to dock to that position and then the

4:37ribosome

4:38scans along and finds the next triplet

4:40spot where

4:42another transfer rna is bound and

4:45eventually you get a

4:46you get a coupling of the two amino

4:48acids that are

4:49placed in close proximity and the

4:51peptide synthesis begins

4:53the process continues sequentially with

4:59as many trnas bound to the mrna as

5:02possible

5:03until the ribosome reaches a signal

5:06which for which there is no there is no

5:09uh

5:10trna coupled to a amino acid and this is

5:13called a stop codon

5:14and so this is the natural process of

5:17generating a polypeptide

5:20there is a class of mutations of course

5:22that introduce

5:23stop codons prematurely in

5:27a messenger rna and unlike the normal

5:30sequence of events

5:31where one reads the mrna and generates

5:34the full length protein which presumably

5:36will be functional

5:38in these disease states where there is a

5:40premature stop codon

5:43the protein can’t be made in its full

5:45length and is either

5:48made in a truncated form which may not

5:50be biologically active

5:52or the messenger rna will undergo a

5:54process called nonsense

5:56mediated mrna decay which will disrupt

5:59it

6:00and you get nothing and unfortunately in

6:02many cases premature stop codons

6:05essentially fork the entire translation

6:07process

6:08and no biologically active protein is

6:10madePremature Stop Codon Mutations in SYNGAP1

6:13now in syngap1 a large fraction maybe

6:16close to half of all the reported

6:18mutations are in fact

6:20premature stop codons and here is simply

6:23a linear

6:24depiction of the syngap protein molecule

6:27with its various domains

6:29and shown as small colored lollipops

6:34at various locations along the protein

6:37are the various stop codon mutations

6:39that have been

6:40reported and these stop codon mutations

6:42may involve

6:43different amino acid coating triplets

6:46in the sequence most commonly are

6:50glutamine to stop codon mutations

6:53and arginine to stop codon mutations but

6:56there are

6:57representatives of very much all of the

7:00possible

7:02stop codon types so if there was a way

7:05to repair these individual mutations

7:09one might be able to allow the

7:10translation process

7:12to continue reading through

7:16that stop codon and not make a truncated

7:18protein but perhaps make the full length

7:20protein which may hopefully be

7:22functional

7:23now there’s been a number of

7:24opportunities or our efforts i should

7:27say

7:27to develop small molecule

7:30therapeutics to try to force

7:33the ribosome to read through a stop

7:36codon

7:37and and those have worked in

7:40the cell systems but i think they’ve run

7:43into trouble when

7:45they’ve been moved toward clinical

7:48applications

7:49and so read through technology driven by

7:52small molecules has not

7:54really earned the respect of

7:58the therapeutic world so one needs

8:00another

8:01strategy to tackle this particular type

8:04of mutation

8:05and this is where the brilliant mind of

8:09my colleague

8:10chris ahern comes in so i’m going toUsing transfer RNA (TRNA) to repair PTC

8:11hand the baton to chris and he’s going

8:13to

8:14explain to you what uh he does after he

8:16unmutes

8:17yeah i’ve unmuted thanks al for that

8:19very elegant introduction to molecular

8:21biology and uh thanks as well the

8:22organizers for letting us

8:24tag team and kind of bring to your

8:26attention this really conceptual

8:28uh level of a therapeutic that we’re

8:31working on at this point to develop and

8:32we’re pointing it towards syngap as well

8:34as

8:34a number of other proteins um so the

8:37premise for the the

8:38the idea that that we have of using

8:40transfer rnas as al discussed

8:43involves this idea from human genetics

8:45that we now know that there are many

8:47different genes for human trnas as many

8:50as 450 different trnas so

8:52as al was showing you know you have a

8:55trna that decodes

8:56a triplet codon there are actually many

8:59different types of trna that can decode

9:00those triplet codons

9:02so for instance with arginine there are

9:04more than 30 different types

9:06of trnas which are unique sequences yet

9:08they all possess

9:10the commonality of decoding an arginine

9:12codon to

9:13an arginine uh in encoding a in a

9:15polypeptide and

9:16so we decided to do is to take advantage

9:18of that biological diversity and

9:20to construct a platform in a biological

9:23screen such that if we could audition

9:26the ability of trnas to tolerate

9:29mutations within this anti-codon loop

9:31that we’re pointing to here on the left

9:33side if

9:34al can run the screen i’m not sure if he

9:36if he wants

9:37yeah so there’s an anticodon region of

9:39the transfer rna

9:41and this is the part that engages into

9:42the mrna

9:44and decodes uh the triplet codon and

9:46then allows for the encoding of

9:47the amino acid and so what we did is we

9:50systematically

9:51altered the anticodons of transfer rnas

9:55such that they would no longer suppress

9:57their cognate amino acid codon

9:59but instead suppress a triplet stop

10:02codon

10:03and we chose the ones that the 10

10:06families of trnas which are uniquely

10:08vulnerable to conversion to stop codons

10:11and so what we did is we changed all

10:13those systematically

10:14to stop codon suppressors depending on

10:16what disease stop

10:18was most relevant and then we built a

10:20screen in

10:21human embryonic kidney cells such that

10:24we had a reporter

10:25a nanoluciferase which is an enzyme and

10:27that enzyme when it’s fully functional

10:30makes a fluorescent substrate and so

10:32what we can do is if we put a stop codon

10:34in that enzyme we can look at the

10:37ability of transfer rnas in human cells

10:40to rescue that stop codon by making the

10:42full length enzyme and thus having a

10:44fluorescent output

10:46with the idea being um that it’s in the

10:48right

10:49environment such that you know we will

10:51be able to then learn more about which

10:53trnas are

10:54are going to be effective for this

10:55conversion and as you may guess

10:57many of them are actually not tolerant

10:58but we were surprised to find that many

11:00actually

11:01are and so we go to the next slideIdentification of Multiple tRNA for PTC Repair

11:04and so this is now i know it’s a data

11:06complex

11:07slide but what you’re looking at here is

11:09by color first

11:11each one of these individual colors are

11:13different families of transfer rna genes

11:16and so this for instance in the upper

11:17left these are glycine trnas so

11:19all those bars are actually looking at

11:22the activity

11:23of those different trnas and on the

11:26bottom it’s a log scale

11:28so what you’re looking at here for each

11:29one of those in each one of these

11:31columns there’s a red dotted line and

11:32that means there’s no activity over

11:34background

11:34for those classes of transfer rnas but

11:37what you can see is for instance in the

11:39glycines and this is a log scale

11:41we have three trnas which successfully

11:43decode

11:44uga stops at over a hundred to a

11:47thousand fold

11:48over background now notably for syngap

11:51arginine

11:52this family of transfer rnas was

11:53actually very tolerant

11:55of being converted into uga uh stop

11:58codon suppressors

12:00the ones that work versus the ones that

12:02do not work is very non-obvious we

12:03weren’t able to predict this outcome

12:05so we really needed to do this full

12:07screen

12:08and so when we look at this entire data

12:10set this is now a platform of transfer

12:12rna

12:13novel sequences within this data set we

12:16have potentially

12:17a genetic repair mechanism for every

12:20known

12:21human premature termination codon within

12:24this library and for many of these

12:26families

12:26we have multiple different transfer rnas

12:29that can be auditioned for their ability

12:31to rescue specific stop codons a note on

12:34the transfer rnas themselves they’re

12:36actually quite small

12:37if it wasn’t obvious for males talk

12:38they’re about 75 to 80 bases

12:41so in terms of payload for aav we can

12:43fit multiple

12:44transfer rnas within in within a payload

12:47and also

12:48they don’t really rely on promoters in

12:50the classical sense that we would

12:52normally be driving a gene

12:53expression they just have a small maybe

12:5575 base per liter sequence

12:58so the whole kind of deliverable unit as

13:00it were is really quite compact

13:02and so the idea of uh you know what can

13:06be delivered

13:06we have a a really a a good kind of

13:09buffet

13:10of genetic material that that can be

13:12brought in and what we’re doing here is

13:14is

13:14what we do is we would essentially

13:16convert

13:18the stop site back to its cognate amino

13:20acid and

13:21really making a wild type protein and

13:24this will be based on the

13:25mrna itself that’s being expressed in

13:28the cell so there’s no chance for up

13:30regulation

13:31uh of the member of the protein that’s

13:32being expressed which is a big thing we

13:34worry about in ion channels where

13:36which is where my main expertise is but

13:38also that we know that we’re making at

13:40the end of the day a wild type protein

13:42so then the main concern that we have

13:44going forward is you know what about

13:46real stops and i’ll get to that in a

13:47second but

13:48what i’d like to just kind of show you

13:49uh in the meantime is you know seeing is

13:51believing

13:52and so what i’d like to share with you

13:53is just what do these transfer rnas look

13:55like in terms of syngap mutations and so

13:57we’ll

13:58go to the next slide and so what we didEngineered tRNAs for Common SYNGAP1 PTC

14:01is we took

14:02some of our trnas out of our library and

14:04we’re looking at gfp now and so we put

14:06different stop codons into gfp and we

14:08looked at

14:08we could rescue them so on the left we

14:10have an image of wild-type gfp

14:12transfected into hek cells

14:14when you throw a stop codon in there uh

14:17the cells are fine

14:18as you can see on the left but they have

14:19no fluorescence because gfp has been

14:21terminated

14:22so now all we do is if we co-express one

14:25of our trnas from our library in this

14:27case we we pulled out i believe

14:28it’s an arginine or is it a glutamine so

14:30in this case it was one of our top

14:31performing arginine trnas

14:33and all we need to do is co-express this

14:35arginine trna

14:37and we rescue almost near wild-type

14:39levels of gfp

14:41and hex cells and so the same can be

14:43shown i think we have some glutamine

14:45data

14:45um that we also did yep and so here’s

14:47some glutamine data

14:48where just all we do is we co-express

14:50this as a different stop codon this is

14:52the amber stop tag or uag and rna

14:54language

14:55so we can rescue this glutamine

14:57completely or

14:58really well close back to wild type

15:00levels and so what we have here is a

15:02as a library or a platform to to rescue

15:05but the most important thing we need to

15:06convince ourselves about are off target

15:08effects

15:09every protein as al showed ends with the

15:12real stop

15:12and we don’t want to read through those

15:14real stop codons because that would

15:15cause systematic

15:17uh elongation of the proteome and that

15:19would be very bad in a biological

15:21sense or therapeutic and so we wanted to

15:23do is we wanted to look at

15:25the the read through of real stop codons

15:27and and to do that

15:28we turned to a method called ribosome

15:30rhymosomal profiling

15:32assay and so with ribosomal profilingAssessing Read-through of Real Stops: Ribosomal Profiling

15:34what you do

15:36is you can actually monitor where all

15:37the ribosomes those little organelle

15:39units that al was describing in the

15:40beginning of the talk

15:41all those different ribosomes they’re

15:43scanning rna throughout the entire cell

15:45thousands of transcripts

15:47many different ribosomes sitting on that

15:49rna

15:50and what you can do is if you isolate

15:52that rna from a cell

15:54you can then cleave away all the areas

15:55where there’s no uh

15:57ribosomes and then sequence that little

15:59bit that footprint

16:00where the ribosome is sitting and then

16:02you can get an assay of

16:03where else are all these ribosomes with

16:06the hypothesis that if we’re

16:08reading through real stop codons you’d

16:10start to see

16:11ribosomes showing up after the three

16:14prime stop

16:15and so this is just a summary of the of

16:16the data from human embryonic kidney

16:18cells

16:19over expressing a variety of different

16:21trna suppressors

16:23and what you can see is a sawtooth

16:24activity is essentially um

16:26the ribosome hopping down the end of

16:28these transcripts and these are all the

16:30transcripts lined up

16:31bioinformatically from these cells and

16:33you can see they’re hopping down the the

16:35last codons

16:36of their reading frames and then they

16:38start to slow down near the stop site

16:40and then they

16:40fall off and in the presence of these

16:43trnas

16:44you see no evidence of significant

16:46read-through of any kind

16:47at these real stop codons and i’d love

16:49to there’s some mechanistic reason why

16:51this

16:51is taking place we think but i don’t

16:53really have time to go into it for the

16:54purposes of brevity of this talk

16:56we can also look at this data another

16:58way um if you go to the next slide

17:00so this is then just again looking at

17:02the the read-through of these

17:04these five different high-performing

17:05trnas as well as a read-through drug at

17:08a low

17:08concentration and what we’re looking at

17:10is read-through of different types of

17:12stop codons

17:13with these different types of trnas and

17:14again we really don’t see much evidence

17:17statistically of

17:18read-through of real stop codons and

17:20that really agrees with our observations

17:22in the lab

17:22where we’ve never seen either if we over

17:24express these trnas and many different

17:26uh cell types as well you know hex cells

17:28we’re now in neurons

17:30they’re really well tolerated uh across

17:32the board

17:33um and so uh the last thing i want to be

17:35able to show you um before i go back to

17:37al is

17:38specificity of encoding um because youHigh Fidelity Rescue of PTC by tRNA: Correct amino acid insertion and stop site

17:41know with ion channel proteins in many

17:42uh uh genes uh neuronal genes you really

17:46need specificity missense mutations

17:48can be as deleterious as nonsense

17:50mutations in many instances and that’s

17:52very much true in the ion channel world

17:54as well as for syn gap and in those

17:55small molecules that i’ll mention

17:57they haven’t really gained traction uh

17:59therapeutically

18:00and one reason for that is they put the

18:02wrong amino acid in so they cause this

18:04ribosomal skipping

18:05but they introduce a missense at the

18:07stop site and so what we wanted to do is

18:09just to take a little peek at

18:10what are these trnas encoding at the

18:13stop sites and so that’s what this data

18:14on the left and figure in panel a is

18:17this is mass spec data this is basically

18:19we can purify

18:20protein a test protein in this case out

18:22of a hex cell that’s been rescued

18:24and we can ask whether or not in one

18:26case we put a a

18:28glycine in that’s the middle panel on

18:29the left or a tryptophan and the masses

18:32work out to be identical to what you

18:33would expect

18:34for correct encoding this is now an area

18:36that we’re going into but

18:38the fidelity of the trna the ability to

18:40suppress

18:41the right amino acid and and put the

18:43right amino acid back where it’s

18:44supposed to be

18:45is intact so that’s a very important

18:47aspect but that’s something that will

18:48need to be tested on a case by case

18:50basis as we go look at different genes

18:52but it looks like the fidelity is there

18:54we’re not hitting real stops and we’re

18:55also getting the right amino acid in

18:57if we look at panel b here um what we’ve

19:00been able to do is just

19:01look at are we hitting the right stop

19:02codon right so we then we put different

19:05stop codons

19:05in this luciferase gene and when we

19:08recode this

19:09glycine trna to suppress ugas it

19:12suppresses ugas

19:14even and then in panel c when we compare

19:16this to

19:17some of these read-through drugs even if

19:20you can guess that they’re working maybe

19:21a little bit

19:22so we have gentamicin there we have a

19:23little bit of rescue g418 is an

19:25experimental compound

19:26but then even compared to these trnas

19:28it’s not even close

19:30so the trnas that do a much better job

19:32of suppressing

19:33they put the right amino acid in and so

19:35as in terms of like a biological vector

19:38we think they have a lot of promise for

19:39stop codons because as i was mentioning

19:42there’s a lot of different you know

19:44positions architecturally within

19:46syngap they’re all different they have

19:47all different contexts they’re all

19:48different amino acids

19:50and we don’t necessarily need to

19:51completely understand the complex

19:52molecular genetics and physiology of

19:54syngap

19:55to know that they all share a common

19:57mechanistic basis for the dysfunction

19:59and we see this as a potential way to at

20:01least start rescuing some of these top

20:03codons

20:04and so with that i’ll go back to alRescuing SYNGAP1 PTC by tRNA

20:12thank you chris um so i think just in

20:14the last couple of minutes i’ll just

20:16share with you

20:16kind of the vision that we have going

20:19forward

20:20to apply this technology to syngap1

20:23the premature stop codon so again i

20:25showed this before

20:26this is simply a linear map of the

20:28protein showing its various domains

20:31uh decorated by the location

20:35of various stock codons the two that we

20:37think would be most

20:38uh valuable to target first would be the

20:41arginine

20:42to stop and the glutamine to stop given

20:45that they represent

20:46more than 60 65 percent of all known

20:50uh syngap1 mutation premature

20:53mutation types uh in in the gene uh so

20:56we envision

20:57producing uh eight different syngap

21:00mutations

21:02for arginine and four glutamine to stop

21:04codons express them in hex cells

21:06and then use the trna technology

21:09to see if we can’t rescue them and the

21:12readouts that we’ve envisioned will be

21:14simply can we restore

21:16the synthesis of folding syngap protein

21:19in the cells

21:21using immunoblots to assess that and if

21:24that’s possible maybe we can also

21:26demonstrate using an enzymatic activity

21:28assay the restoration of rask gap

21:32enzymatic activity um and then as chris

21:34wright

21:35highlighted it’s important to

21:36demonstrate the fidelity

21:38of the repair that the stop codon has

21:41been rescued with the correct amino acid

21:44and for that proteomic analysis can be

21:46done and then lastly to make sure that

21:48the

21:49native stop codon isn’t read through

21:51this

21:52ribosome footprinting strategy is what

21:54we have in mind

21:55these are in vitro experiments in

21:57heterologous cells

21:59the natural next step would be to use uh

22:01also

22:02heterologous in v sorry in vitro

22:04experiments but to use

22:06neurons and so to derive human neurons

22:08as dr

22:09koba had explained one can use ips cell

22:12technology

22:13which we do routinely in my lab to

22:14generate both cortical excitatory and

22:16cortical inhibitory neurons

22:19and so we’ve imagined generating these

22:21neurons from patient-derived

22:23uh ips cells that have premature stop

22:26codon mutations in syngap1

22:29and i’m grateful to some members of the

22:32field who’ve actually offered

22:33to share with us some of the existing

22:36cell lines that would

22:38be valuable in this regard

22:42chris’s lab engineers had no associated

22:45virus with

22:46multiplexed tr recoded trnas

22:50that can be engineered to go into

22:52neurons and then again the neurons could

22:54be in

22:55interrogated with immunoblot strategies

22:57to see if

22:58full length syngap protein’s been

23:00restored maybe functionally

23:02and also importantly to look at neuron

23:05morphology and culture

23:07with and without the rescue trna uh then

23:10last but not least of course if the in

23:11vitro experiments were

23:13successful one would want to go in beach

23:15in bevo

23:16and so uh for this we would have to

23:18engineer a mouse

23:19with the corresponding premature stop

23:23codon mutations

23:24none of these are in existence at the

23:26moment and then if that was available

23:28we’d certainly want to try

23:30to do in vivo delivery using aav

23:34viral technology to deliver the trnas to

23:36the mouse brain

23:38and again assess restoration of syngap

23:40active

23:41protein and maybe enzymatic activity if

23:43possible ultimately

23:45the goal long term is perhaps to try to

23:48demonstrate

23:49behavioral rescue and mutant mice so

23:51that’s a long

23:53long term goal which i think we’re not

23:54going to be there anytime soon butAcknowledgements

23:57with that i just want to thank people in

23:58my lab that are

24:00queued up and already actively working

24:02on this technology

24:03applied to ion channels in collaboration

24:05with dr ahern

24:07and to acknowledge dr ahern’s team and

24:09also some collaborators that we’ve

24:11engaged with recently to try to get some

24:13of this work funded

24:14so with that i again thank the

24:17organizers and uh

24:18thank you for your attention

24:22great thanks to both of you i think

24:24that’s actually really exciting

24:27um we have a thank you not a question in

24:30the q a at the moment uh

24:32hans had a question in the chat actually

24:35that said would it be useful uh a useful

24:38study to determine which premature

24:40truncation codons would be targeted for

24:42nmda and which would avoid nmd

24:45or do we have data that tells us

24:47something about it yeah so i think you

24:48know there’s a there’s sort of a general

24:50dogma

24:51that nmd is engaged for

24:54premature stop codons uh throughout

24:57most of the coding region of most genes

25:00except when you get into the last exon

25:03and you’re very close to the tail end of

25:05the

25:06protein coding region and so that’s the

25:08general dogma

25:10certainly one would want more specific

25:14gene-specific information before

25:17tackling this project and i think that

25:19would be something that would be worth

25:20worth doing right now i don’t have any

25:23of that information

25:24at my disposal but it’s a good question

25:26yeah but and also just to add to what al

25:28was saying and also for the

25:30to address the question is it’s our

25:32working hypothesis

25:33at the moment that the the the activity

25:36of these engineer transfer rnas would

25:38actually antagonize

25:39nonsense mediated decay because we think

25:42that they’re going to infer

25:43interfere with the regulation and the

25:45clientele of nmd proteins that

25:47already recognize those stops and so by

25:49having

25:50this trna present we we’re hoping that

25:53actually will

25:53increase the amount of mrna that’s

25:55present as well but again that’s

25:56something that we don’t have access to

25:58any of that information right now

25:59and so for us the syngap is is a really

26:02a great test protein

26:03to start to look at that because as al

26:05said there’s a there’s a dogma out there

26:06but i think we’re in a position to start

26:08to really

26:09uh test that yeah yep

26:12okay two uh quick questions before we

26:14move on um thanks

26:16for the uh let’s see uh clever

26:19intriguing strategy i’m hoping you can

26:20talk a bit more

26:21about why there isn’t more read through

26:24of real thoughts

26:25isn’t there concern that reads through

26:26even a small subset of targets could

26:28have

26:28important biological consequences yeah

26:31sure um so read through happens actually

26:33normally the the

26:34the body is equipped to deal with

26:36read-through that happens at a few

26:37percent all the time

26:39under normal situations um so there’s a

26:41there’s a couple different reasons why

26:43retro doesn’t happen

26:44that’s because the premature termination

26:45codon is in a really different

26:47environment

26:48uh in terms of the nucleotides that

26:49surround it compared to the evolutionary

26:51uh

26:52footprint of a real stop codon which

26:54itself has a clientele

26:56of proteins these uh stop codon binding

26:59proteins ef1 and ef one

27:01or the or sorry the release factors that

27:04bind

27:05to real stop codons and derail ribosomal

27:07translation

27:08premature termination codons don’t have

27:09that so we think that they’re much more

27:10vulnerable to trna suppression

27:12real stops have a whole protection

27:14mechanism built in that keeps

27:16read through from happening but even

27:18though retro happens at a small level

27:20uh most cells are equipped to to deal

27:22with that small amount of stress so

27:24we’re hoping that we can hit the sweet

27:25spot between those two uh

27:27mechanisms and and currently it seems

27:29like we were able to

27:30to hit that that window again everything

27:33is is a therapeutic window

27:35so you know that that will come down to

27:37testing this this platform that we have

27:39we have multiple different trnas um for

27:42any family so

27:43we can then sample if there are ones

27:44that do tend to read through real stops

27:46more than others we haven’t seen that

27:48but if we do we have other ones we can

27:49fall back on uh so

27:51we’re looking forward to getting into

27:52that work absolutely

27:54great and then last question um from

27:57dave you protect

27:58predict that the ptvs will have the same

28:00phenotypes in mouth

28:02surprising there aren’t these patient

28:04type models yet

28:05and then she notes that her son has a

28:08single nucleotide deletion resulting in

28:10a stop

28:10without a frame shift and is it possible

28:14to engineer a compensatory

28:16frame shift into the trna yes i can

28:19tackle that i mean

28:20certainly it is i mean it’s not that

28:23surprising that there’s not

28:24a premature stop codon mouse model at

28:27this point i think

28:28to model haploid sufficiency uh

28:31of syngap1 it was logical to do just a

28:34global knockout

28:35of of the gene and that that i think has

28:38been done

28:39um you know so i think that’s not that

28:41surprising

28:42the the other part of the question is

28:44about the frame shift and unfortunately

28:46frame shift mutations disrupt the

28:49ribosomes ability to

28:51to to capture the right barcodes

28:54uh because they’re the frame the reading

28:56frame has been just

28:57distorted this technology that we talked

29:00about today would not

29:01correct that and i don’t believe that it

29:04would be

29:05valuable to correct a stop codon that’s

29:08in the wrong reading frame because you

29:10might read through

29:11and make a protein sequence that’s not

29:14natural so this technology would only

29:16work for in-frame

29:20premature stop codon mutations

29:24great thank you both um i think that is

29:27a really intriguing study and uh hopeful

29:30step forward

29:30for syngap1 potential therapy

« All Events